Sarcopenia and Mortality in Critically Ill COVID-19 Patients.
Fatima Al Zahra YaktiLana AbusalahVijay GanjiPublished in: Life (Basel, Switzerland) (2023)
COVID-19 can manifest as either asymptomatic or progressing to a severe phase in some patients, which may require hospitalization. These patients may experience dyspnea and hypoxia, leading to the development of acute respiratory distress syndrome. Studies have reported an increased risk of severe sarcopenia in COVID-19 patients during and after recovery. This narrative review aimed to summarize and synthesize available studies on the association between sarcopenia and mortality in critically ill COVID-19 patients. A total of 22 studies conducted on hospitalized COVID-19 patients were included in this review. Of those, 17 studies reported a direct association, while 5 studies showed no association between sarcopenia and mortality in severe COVID-19 patients. It is important to maintain muscle quality and quantity in defense against COVID-19. The measurement of lean muscle mass should be included in the risk assessment of severely ill COVID-19 patients as part of the therapy plan.
Keyphrases
- sars cov
- end stage renal disease
- acute respiratory distress syndrome
- skeletal muscle
- risk assessment
- ejection fraction
- case control
- coronavirus disease
- chronic kidney disease
- cardiovascular events
- early onset
- peritoneal dialysis
- respiratory syndrome coronavirus
- risk factors
- prognostic factors
- extracorporeal membrane oxygenation
- stem cells
- type diabetes
- patient reported outcomes
- mesenchymal stem cells
- intensive care unit
- endothelial cells
- patient reported
- palliative care
- bone mineral density